{'fraction_non_alphanumeric': 0.019157088122605363, 'fraction_numerical': 0.0, 'mean_word_length': 6.611650485436893, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
ACE inhibitors and angiotensin II receptor antagonists in Crohn’s disease management

An increasing repertoire of therapeutic indications for the angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists has followed an explosion of research exploring the role of the proinflammatory and profibrotic renin–angiotensin–aldosterone system in numerous organ systems. This evidence also implicates the renin–angiotensin–aldosterone system in the pathogenesis of other chronic inflammatory and fibrotic disorders, such as Crohn’s disease. While the research to date supports this hypothesis, further investigation of the renin–angiotensin–aldosterone system in human Crohn’s disease is required before these agents can realistically be investigated in human trials.